QuartzBio Receives Growth Investment from Eir Partners

QuartzBio plans to use the funding to improve its platform and operations by expanding customer support and implementation services, increasing interoperability across CROs, laboratories and clinical systems and enhancing AI-powered automation for workflow management, risk detection, and data quality.

The company will also strengthen analytics and benchmarking tools for multi-trial decision-making while improving enterprise scalability, security, and global compliance capabilities.

As clinical trials become more complex, many sponsors still manage biospecimens and biomarker data across disconnected vendors, systems, and spreadsheets. This fragmentation can create operational gaps that lead to missing or unusable samples, manual tracking processes, delayed discovery of data issues, expensive rework, and slower trial timelines.

QuartzBio was created to solve these operational challenges. Its AI-enabled, vendor-neutral platform brings together sample collection, chain-of-custody tracking, consent management, metadata quality, and biomarker results into a single system, giving biopharma companies real-time visibility and control across their clinical trial portfolios.

QuartzBio is used by a growing number of customers, including several top global pharmaceutical companies, to improve visibility and control across complex clinical trials. The platform helps teams detect, and fix issues early, before they lead to protocol deviations, data loss, or trial delays, while integrating seamlessly into existing workflows.

Customers report near complete visibility into sample collection processes, reducing monitoring work by up to 98%, and lowering manual effort through automated tracking and exception management. These improvement's allow team's to manage more studies without increasing staff and can generate average savings of $250,000–$350,000 per Phase II/III study while helping protect trial timelines and data quality.

Read More:Secludy Raises $4M in Seed Funding Led by Impression Ventures

"Modern clinical development generates unprecedented volumes of data, yet trial risk persists because that data is fragmented, delayed, or unreliable," said Scott Marshall, PhD CEO of QuartzBio. "This investment allows us to double down on delivering a scalable software platform that removes manual oversight protects scientific integrity and materially reduces trial cost, and duration."

"AI is fundamentally transforming clinical development, and sample and biomarker intelligence represents one of its highest impact applications," said Brett Carlson, Founder and Chief Executive Officer of Eir Partners. "QuartzBio has demonstrated both strong product market fit, and tangible economic impact for sponsors managing complex portfolios. By embedding domain specific AI directly into clinical and translational workflows, the company is well positioned to shape how next-generation trials are conducted."

About QuartzBio

Founded by Scott Marshall and Jared Kohler, QuartzBio is a life science technology company that provides sample and biomarker intelligence for clinical-stage biopharma companies. Its vendor-neutral platform combines sample operations and biomarker data into a single system powered by specialised AI tools, helping companies reduce operational risk, accelerate clinical timelines, and improve the reliability of trial outcomes.

Read More:Vector Raises $10M in Series A Funding Led by SignalFire